Seonix Bio receives NATA accreditation
November 12th, 2024
Seonix Bio, a leader in the development of genetic testing for primary open-angle glaucoma (POAG), has received notification of its successful accreditation to ISO 15189 by the National Association of Testing Authorities, Australia (NATA). ISO 15189 is a nationally and internationally recognised standard for quality management in medical laboratories, encompassing technical competence and consistent operational excellence.
“Achieving ISO 15189 accreditation marks a significant milestone in our mission to provide reliable and accurate genetic testing services for glaucoma patients,” said Nick Haan, CEO at Seonix Bio. “This accreditation from NATA reinforces our dedication to maintaining the highest standards of laboratory practice and patient care.”
NATA accreditation ensures that we continue to meet the highest standards for our products and services and demonstrates a commitment to continuous quality improvement.
Seonix Bio receives NATA accreditation
November 12th, 2024
Seonix Bio, a leader in the development of genetic testing for primary open-angle glaucoma (POAG), has received notification of its successful accreditation to ISO 15189 by the National Association of Testing Authorities, Australia (NATA) for its Australian laboratory. ISO 15189 is a nationally and internationally recognised standard for quality management in medical laboratories, encompassing technical competence and consistent operational excellence.
“Achieving ISO 15189 accreditation marks a significant milestone in our mission to provide reliable and accurate genetic testing services for glaucoma patients,” said Nick Haan, CEO at Seonix Bio. “This accreditation from NATA reinforces our dedication to maintaining the highest standards of laboratory practice and patient care.”
NATA accreditation ensures that we continue to meet the highest standards for our products and services and demonstrates a commitment to continuous quality improvement.
